Adult preferences for influenza vaccines with lower likelihood of side effects

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 456-460

  Effler, Paul V ^a   Tomlin, Stephania ^a   Joyce, Sarah ^a   Mak, Donna B ^a  

^a DEPARTMENT OF HEALTH   (Australia)

Author keywords

Adult; AEFI; Consumer; Influenza; Post marketing; Side effects; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGE; AGED; ARTICLE; CONSUMER ATTITUDE; DRUG EFFICACY; DRUG PREFERENCE; HEALTH CARE SURVEY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE REACTION; MIDDLE AGED; PATIENT PREFERENCE; SELF REPORT; YOUNG ADULT; ADOLESCENT; ADVERSE DRUG REACTION; FEMALE; INTERVIEW; MALE; PATIENT ATTITUDE; PSYCHOLOGY; UTILIZATION; VACCINATION;

ADOLESCENT; ADULT; AGED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFLUENZA VACCINES; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; VACCINATION; YOUNG ADULT;

EID: 84896971153     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26835     Document Type: Article

References (21)

1. Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011. http://bmjopen.bmj.com/ content/ early/2011/05/28/bmjopen-2010-000016.full (accessed 12 June 2013).
2. Maraskovsky E, Rockman S, Dyson A, Koernig S, Becher D, Morelli AB, Barnden M, Camuglia S, Bodle J, Vandenberg K, et al. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine. Vaccine 2012; 30:7400-6; PMID:23063831; http:// dx.doi.org/10.1016/j.vaccine.2012.09. 083
3. Petousis-Harris H, Poole T, Turner N, Reynolds G. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance. Vaccine 2012; 30:4945-52; PMID:22664224; http://dx.doi.org/10.1016/j. vaccine.2012.05.052
4. Spila-Alegiani S, Salmaso S, Rota MC, Tozzi AE, Raschetti R. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination. Vaccine 1999; 17:1898-904; PMID:10217587; http://dx.doi. org/10.1016/S0264-410X(98)00467-8 (Pubitemid 29172358)
5. Leeb A, Carcione D, Richmond PC, Jacoby P, Effler PV. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults. Vaccine 2011; 29:7920-4; PMID:21864621; http://dx.doi. org/10.1016/j.vaccine.2011.08. 073
6. McEvoy SP. A retrospective survey of the safety of trivalent influenza vaccine among adults working in healthcare settings in south metropolitan Perth, Western Australia, in 2010. Vaccine 2012; 30:2801-4; PMID:21920401; http://dx.doi.org/10.1016/j. vaccine.2011.09.001
7. Beyer WE, Palache AM, Osterhaus AD. Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature. Clin Drug Investig 1998; 15:1-12; PMID:18370460; http:// dx.doi.org/10.2165/00044011-199815010-00001 (Pubitemid 28073487)
8. Joint Australian Technical Advisory Group On Immunisation (ATAGI) And Therapeutic Goods Administration. (TGA) Seasonal Influenza Vaccine Safety Ad Hoc Working Group Review of Data on the Safety Of Seasonal Influenza Vaccines, Particularly Fluvax (CSL Biotherapies) in Adults and Children >10 Years. Working Group Report Published 10 February 2012 http://www.immunise.health.gov. au/internet /immunise/publishing.nsf/Content/review-fluvax
9. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. JAMA 1990; 264:1139-41; PMID:2200894; http:// dx.doi.org/10.1001/jama. 1990.03450090075029
10. Centers for Disease Control and Prevention (CDC). Influenza vaccination and self-reported reasons for not receiving influenza vaccination among Medicare beneficiaries aged > or =65 years-United States, 1991-2002. MMWR Morb Mortal Wkly Rep 2004; 53:1012-5; PMID:15525898
11. Jones TF, Ingram LA, Craig AS, Schaffner W. Determinants of influenza vaccination, 2003-2004: shortages, fallacies and disparities. Clin Infect Dis 2004; 39:1824-8; PMID:15578406; http://dx.doi. org/10.1086/427153 (Pubitemid 39657263)
12. Ehrenstein BP, Hanses F, Blaas S, Mandraka F, Audebert F, Salzberger B. Perceived risks of adverse effects and influenza vaccination: a survey of hospital employees. Eur J Public Health 2010; 20:495-9; http://dx.doi.org/10. 1093/eurpub/ckp227; PMID:20089677
13. Nichol KL, Hauge M. Influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 1997; 18:189-94; PMID:9090547; http://dx.doi. org/10.1086/647585 (Pubitemid 127469871)
14. Kara A, Devrim I, Celik T, Akca T, Tezer H, Simsek OP, Kutluk T, Kale G, Secmeer G. Influenza vaccine adverse event and effect on acceptability in pediatric residents. Jpn J Infect Dis 2007; 60:387-8; PMID:18032840 (Pubitemid 350177146)
15. Yeager DP, Toy EC, Baker B 3rd. Influenza vaccination in pregnancy. Am J Perinatol 1999; 16:283-6; PMID:10586981; http://dx.doi. org/10.1055/s-2007- 993873
16. Taylor A, Wilson D, Dal Grande E, Gill T. National Influenza Survey (A population survey of vaccination uptake in Australia, October 2000. Available at: http://health.adelaide.edu.au/pros /docs /reports / general/ vaccinationnationalinf luenzasurvey.pdf Accessed 17 June 2013.
17. Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and metaanalysis. Vaccine 2011; 29:5785-92; http://dx.doi. org/10.1016/j.vaccine.2011.05.040; PMID:21624411
18. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59(RR-8):1-62; PMID:20689501
19. Liang XF, Li L, Liu DW, Li KL, Wu WD, Zhu BP, Wang HQ, Luo HM, Cao LS, Zheng JS, et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 2011; 364:638-47; http://dx.doi.org/10.1056/ NEJMoa1008553; PMID:21288090
20. Health Survey Unit. Epidemiology Branch, Public Health Division, Department of Health WA. The WA Health and Wellbeing Surveillance System, Design and Methodology Technical Paper, Series No 1, September 2011 -Version 2. Available at http:// www.health.wa.gov.au/publications /documents / Technical%20paper%20no%201%20Design%20 and%20Methodology.pdf. Accessed 12 June 2013.
21. Dal Grande E, Taylor AW. Sampling and coverage issues of telephone surveys used for collecting health information in Australia: results from a face-to-face survey from 1999 to 2008. BMC Med Res Methodol 2010; 10:77; PMID:20738884; http://dx.doi. org/10.1186/1471-2288-10-77